Cargando…
Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation
Repositioning of approved drugs for identifying new therapeutic purposes is an alternative, time and cost saving strategy to classical drug development. Here, we screened a library of 786 FDA-approved drugs to find compounds, which can potentially be repurposed for treatment of T cell-mediated autoi...
Autores principales: | Voss, Linda, Guttek, Karina, Reddig, Annika, Reinhold, Annegret, Voss, Martin, Schraven, Burkhart, Reinhold, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821167/ https://www.ncbi.nlm.nih.gov/pubmed/33488629 http://dx.doi.org/10.3389/fimmu.2020.616570 |
Ejemplares similares
-
Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021) -
Zinc Aspartate Induces IL-16 Secretion and Apoptosis in Human T Cells
por: Reinhold, Dirk, et al.
Publicado: (2021) -
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage
por: Reddig, Annika, et al.
Publicado: (2021) -
Immune Cell-Type Specific Ablation of Adapter Protein ADAP Differentially Modulates EAE
por: Rudolph, Jochen, et al.
Publicado: (2019) -
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)